Supplemental use of optical diffusion breast imaging for differentiation between benign and malignant breast lesions. AJR, Sept 2011, vol. 197(3), p. 732-739.
Moon, JH, et al.
http://www.ajronline.org/content/197/3/732.abstract?rss=1
The objective of this study was to prospectively evaluate the diagnostic accuracy of optical diffusion breast imaging in patients who underwent conventional ultrasound followed by surgery or biopsy.
Thursday, 8 September 2011
Image guided preoperative hookwire localization of nonpalpable extramammory lesions
Image guided preoperative hookwire localization of nonpalpable extramammory lesions. AJR, Sept 2011, vol. 197(3), p. W525-W527
Kelan, KJ, et al.
http://www.ajronline.org/content/197/3/W525.abstract?rss=1
Imaging-guided hookwire localization of nonpalpable lesions in the breast is frequently performed preoperatively. Outside the breast, this procedure is useful for planning resection of lesions in anatomic regions without intrinsic landmarks. The purpose of this study was to review an experience with hookwire localization of nonpalpable extramammary lesions.
Kelan, KJ, et al.
http://www.ajronline.org/content/197/3/W525.abstract?rss=1
Imaging-guided hookwire localization of nonpalpable lesions in the breast is frequently performed preoperatively. Outside the breast, this procedure is useful for planning resection of lesions in anatomic regions without intrinsic landmarks. The purpose of this study was to review an experience with hookwire localization of nonpalpable extramammary lesions.
Wednesday, 3 August 2011
Management of uncommon chemotherapy-induced emergencies
Management of uncommon chemotherapy-induced emergencies. The Lancet Oncology, Aug 2011, vol. 12(8), p.806-814.
Morgan, C., et al.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70208-4/abstract?rss=yes
Chemotherapy can induce various clinical emergencies. Prompt recognition and management of these adverse events are important for avoiding further morbidity and mortality.
Morgan, C., et al.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70208-4/abstract?rss=yes
Chemotherapy can induce various clinical emergencies. Prompt recognition and management of these adverse events are important for avoiding further morbidity and mortality.
Mastectomy and reconstruction in stage IV breast cancer
Mastectomy and reconstruction in stage IV breast cancer: A survery of UK breast and plastic surgeons. The Breast, Aug 2011, vol. 20(4), p.373-79.
Durrant, CAT, et al.
http://www.thebreastonline.com/article/PIIS0960977611000452/abstract?rss=yes
The number of women with stage IV disease who have breast reconstruction is small. The primary aim of this study was to examine opinions as to the appropriateness of breast reconstruction in this group.
Durrant, CAT, et al.
http://www.thebreastonline.com/article/PIIS0960977611000452/abstract?rss=yes
The number of women with stage IV disease who have breast reconstruction is small. The primary aim of this study was to examine opinions as to the appropriateness of breast reconstruction in this group.
Interest in cavity shaving in breast conservation treatment does not depend on lumpectomy technique
Interest in cavity shaving in breast conservation treatment does not depend on lumpectomy technique. The Breast, Aug 2011, vol. 20(4), p.358-64.
Feron, JG., et al.
http://www.thebreastonline.com/article/PIIS0960977611000300/abstract?rss=yes
In breast conserving surgery (BCS), the usefulness to perform systematic cavity shaving is actively debated. Some investigators argued that systematic cavity shaving could avoid surgical re-excision and make diagnosis of unexpected multifocality. Others argued that usefulness of cavity shaving depends on volumes of resection.
Feron, JG., et al.
http://www.thebreastonline.com/article/PIIS0960977611000300/abstract?rss=yes
In breast conserving surgery (BCS), the usefulness to perform systematic cavity shaving is actively debated. Some investigators argued that systematic cavity shaving could avoid surgical re-excision and make diagnosis of unexpected multifocality. Others argued that usefulness of cavity shaving depends on volumes of resection.
Optimal adjuvant therapy for very young breast cancer patients
Optimal adjuvant therapy for very young brest cancer patients. The Breast, Aug 2011, vol. 20(4), p.297-302.
Francis, PA.
http://www.thebreastonline.com/article/PIIS0960977611001032/abstract?rss=yes
Approximately one in forty women diagnosed with early breast cancer is very young (<35 years) and this age group has a worse prognosis. The inferior prognosis in very young women appears to have two aspects. Very young women present more frequently with tumors with adverse histo-pathologic features. However, even when the histo-pathologic features appear favorable (ie. endocrine responsive tumors), analyses suggest that very young women with hormone receptor positive tumors are a sub-group at particular risk for adverse outcomes, compared to older premenopausal women with similar tumors
Francis, PA.
http://www.thebreastonline.com/article/PIIS0960977611001032/abstract?rss=yes
Approximately one in forty women diagnosed with early breast cancer is very young (<35 years) and this age group has a worse prognosis. The inferior prognosis in very young women appears to have two aspects. Very young women present more frequently with tumors with adverse histo-pathologic features. However, even when the histo-pathologic features appear favorable (ie. endocrine responsive tumors), analyses suggest that very young women with hormone receptor positive tumors are a sub-group at particular risk for adverse outcomes, compared to older premenopausal women with similar tumors
How not to neglect the care of the elderly breast cancer patients
How not to neglect the care of the elderly breast cancer patient. The Breast, Aug 2011, vol. 20(4), p.293-96.
Tahir, M., et al.
http://www.thebreastonline.com/article/PIIS0960977611000907/abstract?rss=yes
Breast cancer is one of the leading causes of cancer mortality in women. Its incidence increases with increasing age; those over 70 years constitute more than one-third of the current breast cancer population. Despite significant advances in the field of breast cancer treatment, elderly patients have seen neither a meaningful improvement in treatment strategies, nor a decline in breast cancer-specific mortality.
Tahir, M., et al.
http://www.thebreastonline.com/article/PIIS0960977611000907/abstract?rss=yes
Breast cancer is one of the leading causes of cancer mortality in women. Its incidence increases with increasing age; those over 70 years constitute more than one-third of the current breast cancer population. Despite significant advances in the field of breast cancer treatment, elderly patients have seen neither a meaningful improvement in treatment strategies, nor a decline in breast cancer-specific mortality.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer
Four year follow-up of trastuzumab plus adjuvant chemotherpy for operable HER2 positive breast cancer: Joint analysis of NNCTG N9831 and NSABP B-31. J Clin Oncol published online before print July 18, 2011
Wan, Y. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/19/Four-year-follow-up-of-trastuzumab-plus-adjuvant-chemotherapy-for-operable-HER2-positive-breast-cancer-Joint-analysis-of-NCCTG-N9831-and-NSABP-B-31/
Four large trials evaluating adjuvant trastuzumab for HER2-positive breast cancer demonstrated significant improvements in disease-free survival (DFS; 36% to 52% reduction in DFS events) and overall survival (OS; 33% to 37% reduction in deaths). These data has led adjuvant trastuzumab becoming the foundation of care for HER2-positive early breast cancer.
Wan, Y. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/19/Four-year-follow-up-of-trastuzumab-plus-adjuvant-chemotherapy-for-operable-HER2-positive-breast-cancer-Joint-analysis-of-NCCTG-N9831-and-NSABP-B-31/
Four large trials evaluating adjuvant trastuzumab for HER2-positive breast cancer demonstrated significant improvements in disease-free survival (DFS; 36% to 52% reduction in DFS events) and overall survival (OS; 33% to 37% reduction in deaths). These data has led adjuvant trastuzumab becoming the foundation of care for HER2-positive early breast cancer.
High-dose chemotherapy with stem-cell support gives no apparent survival benefit in breast cancer
High-dose chemotherapy with stem-cell support gives no apparent survival benefit in breast cancer. J Clin Oncol, published early online 18 July 2011
Glare, J. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/High-dose-chemotherapy-with-stem-cell-support-gives-no-apparent-survival-benefit-in-breast-cancer/
Two meta-analyses published early online by the Journal of Clinical Oncology examine the evidence on high-dose chemotherapy with stem-cell support in high-risk primary and in metastatic breast cancer: both found that while the technique produced small increases in relapse-free survival, it did not significantly prolong overall survival.
Glare, J. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/High-dose-chemotherapy-with-stem-cell-support-gives-no-apparent-survival-benefit-in-breast-cancer/
Two meta-analyses published early online by the Journal of Clinical Oncology examine the evidence on high-dose chemotherapy with stem-cell support in high-risk primary and in metastatic breast cancer: both found that while the technique produced small increases in relapse-free survival, it did not significantly prolong overall survival.
Triptorelin reduces risk of ovarian failure due to chemotherapy for breast cancer
Triptorelin reduces risk of ovarian failure due to chemotherapy for breast cancer. JAMA 2011; 306: 269-76
Glare, J. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/Triptorelin-reduces-risk-of-ovarian-failure-due-to-chemotherapy-for-breast-cancer/
Breast cancer in younger women is less common, about 12% aged under 45 years, but they are at increased risk of an adverse outcome and therefore most will receive intensive systemic chemotherapy. This may cause early ovarian failure leading to premature menopause: it is estimated that each month of chemotherapy translates into 1.5 years of lost reproductive life. There are no proven standard strategies for preventing this toxicity, however experimental work and pilot studies suggest that suppressing ovarian function with a gonadotropin-releasing hormone (GnRH) analogue might be helpful. This trial examined the hypothesis.
Glare, J. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/Triptorelin-reduces-risk-of-ovarian-failure-due-to-chemotherapy-for-breast-cancer/
Breast cancer in younger women is less common, about 12% aged under 45 years, but they are at increased risk of an adverse outcome and therefore most will receive intensive systemic chemotherapy. This may cause early ovarian failure leading to premature menopause: it is estimated that each month of chemotherapy translates into 1.5 years of lost reproductive life. There are no proven standard strategies for preventing this toxicity, however experimental work and pilot studies suggest that suppressing ovarian function with a gonadotropin-releasing hormone (GnRH) analogue might be helpful. This trial examined the hypothesis.
Thursday, 14 July 2011
Role of mammography in the triple assessment of single-quadrant breast symptoms
Role of mammography in the triple assessment of single-quadrant breast symptoms.
British journal of surgery, vol 98(7), p.951-5.
Donnelly, J., et al.
http://onlinelibrary.wiley.com/doi/10.1002/bjs.7490/full
Most women over the age of 35 years referred to a breast clinic have single-quadrant symptoms and undergo mammography (MMG) as part of the triple assessment of these. A proportion of these women has no abnormality clinically or on ultrasonography (P1 U1). The aim of this study was to assess the additional contribution of MMG in diagnosing cancer in patients with P1 U1 findings and to consider whether it is safe to be more selective when requesting MMG.
British journal of surgery, vol 98(7), p.951-5.
Donnelly, J., et al.
http://onlinelibrary.wiley.com/doi/10.1002/bjs.7490/full
Most women over the age of 35 years referred to a breast clinic have single-quadrant symptoms and undergo mammography (MMG) as part of the triple assessment of these. A proportion of these women has no abnormality clinically or on ultrasonography (P1 U1). The aim of this study was to assess the additional contribution of MMG in diagnosing cancer in patients with P1 U1 findings and to consider whether it is safe to be more selective when requesting MMG.
Wednesday, 29 June 2011
Library stock: Association of Breast Surgery Yearbook
2011 Association of Breast Surgery Yearbook available for loan.
Containing articles, reports, audits, education and training features, plus breast cancer screening and prognosis.
Containing articles, reports, audits, education and training features, plus breast cancer screening and prognosis.
Monday, 27 June 2011
2011 RCN Cancer and Breast Care Conference
RCN Cancer and Breast Care Conference 2011
Location: Thistle Marble Arch, Bryantson Street, London, W1H 7EH
Date: 25 November 2011 to 25 November 2011
This event welcomes nurses, APs and HCAs with an interest in cancer and breast care.
Location: Thistle Marble Arch, Bryantson Street, London, W1H 7EH
Date: 25 November 2011 to 25 November 2011
This event welcomes nurses, APs and HCAs with an interest in cancer and breast care.
New England Journal of Medicine: 364 June 2011
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss, et al
N Engl J Med 2011; 364:2381-2391
June 23, 2011
Access the abstract using your Athens username and password
Paul E. Goss, et al
N Engl J Med 2011; 364:2381-2391
June 23, 2011
Access the abstract using your Athens username and password
The Breast Journal: Vol 17 Iss 3 May/June 2011
The Utility of Breast MRI as a Problem-Solving Tool
Edwin J. et al
Abstract
pages 273–280, May/June 2011
Article first published online: 8 APR 2011
Edwin J. et al
Abstract
pages 273–280, May/June 2011
Article first published online: 8 APR 2011
British Journal of Surgery Vol 98 Issue 7 July 2011
Role of mammography in the triple assessment of single-quadrant breast symptoms
Donnelly, J. et al
Volume 98, Issue 7
pages 951–955,
July 2011
Article first published online: 20 Apr 2011
Access these articles using your Athens username and password under 'Institutional login'
Donnelly, J. et al
Volume 98, Issue 7
pages 951–955,
July 2011
Article first published online: 20 Apr 2011
Access these articles using your Athens username and password under 'Institutional login'
Lancet Oncology Vol 12; No 5 May 2011
Preventive therapy for breast cancer: a consensus statement
12 May 2011
pp. 496-503
Cuzick, J. et al
Please contact the Library staff if you require full text access to this article.
12 May 2011
pp. 496-503
Cuzick, J. et al
Please contact the Library staff if you require full text access to this article.
Journal of Medical Screening Vol 18 No 1 May 2011
False-positive mammographic screening: factors influencing re-attendance over a decade of screening
02 May 2011,
Fitzpatrick, P. et al
'A mastectomy for something that wasn't even truly invasive cancer.' Women's understandings of having a mastectomy for screen-detected DCIS: a qualitative study
02 May 2011,
'A mastectomy for something that wasn't even truly invasive cancer.' Women's understandings of having a mastectomy for screen-detected DCIS: a qualitative study
02 May 2011,
Prinjha, S., et al
Abstracts only
The Kings Fund: Improving Cancer Survival Report
Existing differences in cancer survival rates are considered between countries and discusses the reasons for these variations including: stage at diagnosis and diagnostic delay; treatment factors; patient factors; and tumour biology and physiological/biological factors.
The full text of the report is available at:
http://www.kingsfund.org.uk/publications/cancer_survival.html
The full text of the report is available at:
http://www.kingsfund.org.uk/publications/cancer_survival.html
Association of Breast Surgery: Screening Audit 2009-2010
Significant survival improvement shown in the NHS Breast Screening Programme audit for 2009-March 2010.
Click here for the full text link
Click here for the full text link
Subscribe to:
Posts (Atom)